Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Rani Therapeutics Holdings Inc. Class A Common Stock
RANI | US
0.78
USD-0.05
-6.15%
RANI | US
About Rani Therapeutics Holdings Inc. Class A Common Stock
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
09/04/2026
Close
0.78
Open
0.84
High
0.84
Low
0.77
Rani Therapeutics Holdings Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule a drug-agnostic oral delivery platform to deliver a variety of drug substances including large molecules such as peptides proteins and antibodies. Its product pipeline includes RT-101 an octreotide which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-102 a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105 an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110 a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111 an ustekinumab biosimilar for the treatment of various inflammatory conditions. The company was incorporated in 2012 and is headquartered in San Jose California.
View LessRANI | US
Risk
109.7
Sharpe
-0.13
Luna's Score
27/100
Recommendation
Sell
Luna says (RANI | US)
What's Working
Low Market Beta (-0.4 to 0.8)
What's not Working
Negative Momentum (Declining Price)
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Debt to Equity (> 0.75)
High Debt to Asset (> 0.45)
Rich in Valuation (Price to Book > 8)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
144.3%1 month
109.7%3 months
80.3%6 months
377.7%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
30.14
Debt to equity
12.43
Debt to assets
0.81
Ent. to EBITDA
-1.42
Ent. to rev.
84.28
PEG
-
Other Fundamentals
EBITDA
-56.90M
MarketCap
45.14M
MarketCap(USD)
45.14M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-100.00
Ret. on equity
-225.35
Short ratio
10.51
Short perc.
4.89
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
0.54
Range1M
0.72
Range3M
0.86
Volumes: Market Activity
Rel. volume
0.94
Price X volume
1.04M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -1.42 | - | Cheaper |
| Ent. to Revenue | 84.28 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 30.14 | 15.55 | Expensive |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 80.35 | - | Par |
| Debt to Equity | 12.43 | -1.23 | Expensive |
| Debt to Assets | 0.81 | 0.25 | Expensive |
| Market Cap | 45.14M | - | Emerging |
